Last reviewed · How we verify
TolaSure Topical Gel
At a glance
| Generic name | TolaSure Topical Gel |
|---|---|
| Also known as | Active Ingredient BM-3103 |
| Sponsor | BioMendics, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex (PHASE2)
- Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (PHASE1)
- Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants (PHASE2)
- Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TolaSure Topical Gel CI brief — competitive landscape report
- TolaSure Topical Gel updates RSS · CI watch RSS
- BioMendics, LLC portfolio CI